Interview: Yita Lee Ph.D – Deputy Chairman, Sinphar Group; Muh-Hwan Su Ph.D. – Chief Technology Officer, Sinphar Group & General Manager, SynCore Bio, Taiwan

12Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group, and the advantages of SynCore Bio’s integration within Sinphar Group. As an introduction to our international readers, could you provide us with an overview of Sinphar Group and explain its positioning within the Taiwanese pharmaceutical landscape?
"Although Sinphar has been historically focused on generics, our Chairman has been steadily steering the direction of our group toward a more R&D-driven approach for already two decades."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report